AstraZeneca (AZN) announced that the European Commission (EC) has approved Truqap (capivasertib) in combination with Faslodex (fulvestrant) for a breast cancer indication.The EC has approved Truqap in combination with Faslodex for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors have qualifying alterations in the PIK3CA, AKT1 or PTEN genes following recurrence or progression on or after an endocrine-based regimen.Following ...